skip to main content

ES
Last Updated: 12/23/2024

Denosumab

Drug Name(s): Prolia

Class: Biologics

Type: RANK Ligand inhibitor

Used for the treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.

Dosage

Form(s): injection 

60 mg given by injection every 6 month

Special Instructions

Take at least 1,000 mg calcium and 400 IU vitamin D daily.

Injection should be given by a health care provider.

Potential Side Effects

Back pain; bladder infection; high cholesterol; muscle pain; pain in arms and legs

Be Aware

Tell your doctor if you cannot take daily calcium and vitamin D, have had parathyroid or thyroid surgery, plan to have dental surgery or have low blood calcium, kidney disease or trouble absorbing minerals.

Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia (low levels of calcium) following denosumab administration. Your doctor will test before and during treatment. The risk of fractures, including multiple vertebral fractures, increases after discontinuing this drug. This drug may slightly increase your risk of serious infections — including infections of skin, urinary tract, abdomen and ear — and has been associated with a slightly increased risk of malignancies. Severe bone, joint and muscle pain occurs in some patients. Pain or signs of infection may necessitate discontinuing denosumab.

The Arthritis Foundation’s Drug Guide is meant for education — not self-medicating. The Arthritis Foundation does not endorse any products mentioned in this guide. While we endeavor to keep the information up to date, we make no representations or warranties about the completeness of the information provided.